RecruitingInterventionalPhase 2Last updated Aug 13, 2026

Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)

Overview

ClinicalTrials.gov ID: NCT07762586
Lead Sponsor: Rutgers, The State University of New JerseyOTHER
Brief Summary: This study is a two-arm phase II randomized trial investigating patients with luminal subtype muscle-invasive bladder cancer (MIBC) receiving neoadjuvant therapy (NAT) followed by cystectomy compared to those receiving upfront cystectomy.
Study Type: Interventional

Status

Overall Status: Recruiting
Start Date: Jul 10, 2026Actual
Primary Completion Date: Jul 2027Estimated
Completion Date: Jul 2029Estimated

Study Record Dates

First Submitted: May 1, 2026
First Submitted that Met QC Criteria: Aug 7, 2026
First Posted: Aug 13, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 7, 2026
Last Update Posted: Aug 13, 2026Actual
Last Verified: Aug 2026

NCT05776758Active, not recruiting

Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt

NCT03532451Completed

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

NCT02845323Active, not recruiting

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT05137262Active, not recruiting

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

NCT03294304Completed

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

NCT04876313Unknown status

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)